Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model

VANCOUVER, BC -- (Marketwired) -- 04/27/15 -- Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its new fusion protein, APC 103, exhibited enhanced activity over the parent protein in retarding tumor growth in animal studies, comparable to APC 101 which has been the Company's principal point of focus to date.

Because its size is above the renal threshold for elimination from the body, APC 103 may offer an advantage over related smaller proteins, by affording an increased duration of action in vivo. These tests were carried out in conjunction with APC's academic collaborators using the CMS5 fibrosarcoma tumor model.

APC has been engaged in the research and development of in-house product candidates in the area of cancer therapeutics. The Company's platform is based upon a parent protein that has been shown to confer antitumor immunity in animal studies, but requires modification for enhanced activities. 

A major motif that the Company has been developing involves the Foundation Trinity™ concept of targeted therapy, combination therapy and immunotherapy in a single agent. Underscoring this technology is the ability to load APC's protein delivery with chemotherapeutic entities as cargo to be specifically delivered to the target cancer cell.

The Company has sought two distinct types of molecules. One type, exemplified by APC 101, exploits chemical methods to produce entities that have exhibited enhanced activities in animal studies by producing an immune response, demonstrating the immunotherapeutic potential of the Company's approach. Company scientists have now produced another molecular type, a member of a class of molecules which are known as fusion proteins. 

Fusion proteins are molecules that have at least one protein linked to another by means of recombinant DNA technology. APC's goal is to create fusion proteins capable of delivering site-specifically attached chemotherapeutic entities to target cancer cells.

Such protein conjugates are expected to avoid the toxicities associated with small molecule chemotherapeutics which also attack healthy cells, thereby rendering the targeted therapy for the destruction of cancer cells, a "kinder and gentler agent." According to design, they are also expected to display a profile characteristic of an immunotherapeutic.

Allen Krantz, APC's President and CEO, commented: "The fusion protein initiative rounds out our current repertoire of entities for testing which now includes a substantial portfolio of molecular types consisting of conjugated and unconjugated proteins featuring the protein delivery system. The particular fusion proteins the Company has pursued presented considerable technical challenges to obtain purified material, which we now have in hand. APC 103 should augment our current efforts by providing expanded opportunities to combine immunotherapy and diverse chemotherapeutic entities in a single agent."

About APC

APC has been applying its Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent, that can also, in turn, be combined with additional agents to enhance therapies.

To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

   FOR FURTHER INFORMATION PLEASE CONTACT:  Advanced Proteome Therapeutics Corporation Alexander (Allen) Krantz President and Chief Executive Officer Tel: (617) 638-0340

http://www.advancedproteome.com  Scott Young Investor Relations Tel: (705) 888-2756

Source: Advanced Proteome Therapeutics Corporation

You May Also Be Interested In

• WHEELHOUSE SECURES MINORITY INVESTMENT FROM ALIGNMENT GROWTH TO SCALE THE NEXT GENERATION ENTERTAINMENT COMPANY
• Lincoln Educational Services Corporation Schedules First Quarter Earnings Release and Conference Call
• TimelyCare Earns Recognition as One of the World's Best Digital Health Companies, Earns Five Top Workplace Awards